Clozapine-induced agranulocytosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Wider use of clozapine, one of the most effective antipshychotic drugs, is precluded by its propensity to cause agranulocytosis. Currently, clozapine is used for treatment-resistant schizophrenia, with mandatory blood count monitoring for the duration of treatment. Agranulocytosis occurs in up to 0.8% of patients and presents a significant medical challenge, despite decreasing mortality rates. In this paper, we review the epidemiology of clozapine-induced agranulocytosis (CLIA), advances in identifying genetic risk factors, and the preventive measures to reduce the risk of CLIA. We discuss the pathogenesis of CLIA, which, despite receiving considerable scientific attention, has not been fully elucidated. Finally, we address the clinical management and suggest the approach to clozapine re-challenge in patients with a previous episode of neutropenia. With a significant proportion of clozapine recipients in Western hemisphere being Black, we comment on the importance of recognizing benign ethnic neutropenia as a potential impediment to clozapine administration. This review aims to aid haematologists and psychiatrists to jointly manage neutropenia and agranulocytosis caused by clozapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs
Andersohn, F., Konzen, C., & Garbe, E. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00009 · Cited by 479
Reich, D., Nalls, M. A., Kao, W. H. L., Akylbekova, E. L., Tandon, A., Patterson, N., Mullikin, J., Hsueh, W.-C., Cheng, C.-Y., Coresh, J., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000360 · Cited by 423
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
Haematological toxicity of drugs used in psychiatry
Flanagan, R. J., & Dunk, L. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.917 · Cited by 236
The impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141
Blood Dyscrasias Induced by Psychotropic Drugs
(2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815513 · Cited by 100
Research works printed but not linked: 46
- Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209:385–392 · DOI · Paper page
- Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324:746–754 · DOI · Paper page
- Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193–198 · DOI · Paper page
- Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990–998 · DOI
- Meltzer HY (2012) Balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6(3):134–144 · DOI · Paper page
- Lambertenghi-Deliliers G (2000) Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 85:233–237
- Tang YL, Mao PX, Jiang F, Chen Q, Wang CY, Cai ZJ, Mitchell P (2008) Clozapine in China. Pharmacophyschiatry 41:1–9 · doi:10.1055/s-2007-993224
- Honigfeld G, Arellano F, Sethi J et al (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59(suppl.3):3–7
- Li X-H, Zhong X-M, Lu L, Zheng W, Wang SB, Rao WW, Wang S, Ng CH, Ungvari GS, Wang G, Xiang YT (2020) The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med 50:583–594 · DOI
- Kaufman DW, Kelly JP, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anaemia. Oxford University Press Inc, New York
- Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869–874 · DOI · Paper page
- Schulte PF (2006) Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 40:683–688 · DOI
- Latif Z, Jabbar F, Kelly BD (2011) Clozapine and blood dyscrasia. Psychiatrist 35:27–29 · doi:10.1192/pb.bp.109.026054
- Young NS (1994) Agranulocytosis. JAMA 271:935–938 · doi:10.1001/jama.1994.03510360061038
- Munro J, O’Sullivan D, Andrews C et al (1999) Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 175:576–580 · DOI · Paper page
- Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ (1995) HLA associations in clozapine-induced agranulocytosis. Blood 86:1177–1183 · DOI
- Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ (1995) The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86:3835–3840 · doi:10.1182/blood.v86.10.3835.bloodjournal86103835
- Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, Yunis EJ (1997) Tumor necrosis factor constellation polymorphisms and clozapine-induced agranulocytosis in two different ethnic groups. Blood 89:4167–4174 · DOI
- Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR (2011) Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 72:458–463 · DOI
- Legge SE, Hamshere ML, Ripke S et al (2017) Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 22:1502–1508 · DOI
- Legge SE, Walters JTR (2019) Genetics of clozapine-associated neutropenia: recent advances, challenges, and future perspectives. Pharmacogenomics 20:279–290 · DOI
- Gerson SL, Meltzer H (1992) Mechanisms of clozapine-induced agranulocytosis. Drug Saf 7(suppl.1):17–25 · DOI
- Veys P, Wilkes S, Shah S et al (1992) Clinical experience of clozapine-induced neutropenia in the UK. Drug Saf 7(suppl.1):26–32 · doi:10.2165/00002018-199200071-00008
- Guest I, Sokoluk B, MacCrimmon J, Uetrecht J (1998) Examination of possible toxic and immune mechanisms of clozapine-indiced agranulocytosis. Toxicology 131:53–65 · DOI
- Regen F, Herzog I, Hahn E, Ruehl C, le Bret N, Dettling M, Heuser I, Hellmann-Regen J (2017) Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in vitro approach. Toxicol Appl Pharmacol 316:10–16 · DOI
- Gerson SL, Arce CY, Meltzer HY (1994) N-desmethylclozapine: a clozapine metabolite that supresses haemopoiesis. Br J Haematol 86:555–561 · DOI
- Uetrecht JO (1992) Metabolism of Clozapine by neutrophils. Drug Saf 7(suppl.1):51–56 · DOI
- Williams DP, Pirmohamed M, Naisbitt DJ et al (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375–1382
- Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK (2000) Induction of metabolism-dependent and –independent neutrophil apoptosis by clozapine. Mol Pharmacol 58:207–216 · doi:10.1124/mol.58.1.207
- Uetrecht JO, Zahid N, Tehim A, Mim Fu J, Rakhit S (1997) Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 104:117–129 · doi:10.1016/s0009-2797(97)00017-3
- Nooijen PMM, Carvalho F, Flanagan RJ (2011) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychophramacol Clin Exp 26:112–119 · DOI
- Sultan RS, Olfson M, Correll CU, Duncan EJ (2017) Evaluating the effect of the changes in FDA guidelines for Clozapine monitoring. J Clin Psychiatry 78(8):e933–e939 · DOI
- Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188:255–263 · DOI
- Lally J, Malik S, Whiskey E et al (2017) The use of Granulocyte colony-stimulating factor in clozapine rechallenge. A systematic review. J Clin Psychopharmacol 37:600–604 · doi:10.1097/jcp.0000000000000767
- Ingimarsson O, MacCabe JH, Haraldsson M et al (2016) Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry 16:441 · DOI
- Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, Shergill S, MacCabe JH (2015) Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry 76:e1410–e1416 · DOI
- Malik S, Lally J, Ajnakina O, Pritchard M, Krivoy A, Gaughran F, Shetty H, Flanagan RJ, MacCabe JH (2018) Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophr Res 195:267–273 · DOI
- Kanaan RA, Kerwin RW (2006) Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 67:756–760 · DOI
- Manu P, Sarpal D (2012) Muir O et al: when can patients with potentially life-threatening adverse effects be rechallenged with clozapine? Schizophr Res 134:180–186 · DOI · Paper page
- Myles N, Myles H, Xia S, Large M, Bird R, Galletly C, Kisely S, Siskind D (2019) A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aus NZ J Psych 53:403–412 · DOI
- Hsieh MM, Tisdale JF, Rodgers GP, Young NS, Trimble EL, Little RF (2010) Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 28:1633–1637 · DOI
- Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007) Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. Ann Intern Med 146:486–492 · DOI · Paper page
- Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK, Ruzinski JT, Rhim JS, Martin TR, Goodman RB (2003) Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo. J Immunol 170:5244–5251 · DOI · Paper page
- Shoenfield Y, Alkan ML, Asali A et al (1988) Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 41:273–277 · DOI
- Whiskey E, Olofinjana O (2011) Taylor D:The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine. J Psychopharmacol 25:842–845 · doi:10.1177/0269881110364267
- Legge SE, Hamshere ML, Hayes RD, Downs J, O'Donovan MC, Owen MJ, Walters JTR, MacCabe JH (2016) Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res 174:113–119 · DOI
Cited by
Correll, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022) · CNS Drugs · doi:10.1007/s40263-022-00932-2 · Cited by 162
Dong, S., Schneider-Thoma, J., Bighelli, I., Siafis, S., Wang, D., Burschinski, A., Schestag, K., Samara, M., & Leucht, S. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01654-2 · Cited by 68
Primum non nocere: The onus to characterize the potential harms of psychedelic treatment
Ghaznavi, S., Ruskin, J. N., Haggerty, S. J., King, F., & Rosenbaum, J. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230914 · Cited by 12
Clozapine-Induced Acute Interstitial Nephritis
Ragg, J., Innes, S., Bannon, F., & Hope, J. (2026) · Journal of clinical psychopharmacology · doi:10.1097/jcp.0000000000002192 · Cited by 2
Metadata
- Authors
- Mijovic, A., & MacCabe, J. H.
- Venue
- Annals of Hematology
- Published
- 2020-08-20
- Volume
- 99
- Issue
- 11
- Pages
- 2477-2482
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- OpenAlex
- W3080924193
- Cited by
- 157
- References
- 8
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- King's College London
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clozapine-induced agranulocytosis. https://app.cochat.ai/papers/10.1007/s00277-020-04215-y
- The paper
- Mijovic, A., & MacCabe, J. H. (2020). Clozapine-induced agranulocytosis. Annals of Hematology. https://doi.org/10.1007/s00277-020-04215-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.